drugset
drugset / Trial / NCT00446511

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511 ↗

Phase 3 Completed 250 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension.

Timeline

Start
2007-06
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Enalapril Other / unclassified 10 mg Oral
Subject Enalapril Other / unclassified 20 mg Oral
Subject Enalapril Other / unclassified 40 mg Oral
Subject Valsartan Small molecule 80 mg Oral
Subject Valsartan Small molecule 160 mg Oral
Subject Valsartan Small molecule 320 mg Oral

Indications

hypertensive disorder